ASCO® 2023 Insights: "ARC-7: Randomized Phase 2 Study of Domvanalimab + Zimberelimab ± Etrumadenant vs. Zimberelimab in 1L PD-L1-High mNSCLC"

819 views
June 9, 2023
0 Comments
Login to view comments. Click here to Login